We use a CRISPR screening platform based on adeno-associated virus and the Sleeping Beauty transposon (AAV-SB-CRISPR) to perform in vivo CRISPR screens in primary natural killer (NK) cells across four different tumor models, and identify calcium homeostasis modulator family member 2 (CALHM2) as an NK cellular checkpoint protein.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
209,00 € per year
only 17,42 € per issue
Buy this article
Purchase on Springer LinkInstant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Fig. 1: AAV-SB-CRISPR screens and single-cell RNA sequencing of tumor-infiltrating NK cells jointly identify CALHM2 as an NK cellular checkpoint.
References
Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat. Med.30, 772–784 (2024). A recent clinical trial demonstrating the robust efficacy and superior safety of CAR-NK.
Vivier, E. et al. Natural killer cell therapies. Nature626, 727–736 (2024). Comprehensive review discussing the current status of NK therapy.
Dong, M. B. Systematic immunotherapy target discovery using genome-scale in vivo CRISPR screens in CD8 T cells. Cell178, 1189–1204 (2019). This paper reports an early in vivo CRISPR screens in primary T cells.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ye, L. et al. In vivo CRISPR screening in CD8 T cells with AAV-Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. Nat. Biotechnol.37, 1302–1313 (2019). This paper demonstrates the application of an AAV-SB-CRISPR system in T cells.
Article
CAS
PubMed
PubMed Central
Google Scholar
Download references
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Peng, L. et al. In vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy. Nat. Biotechnol. https://doi.org/10.1038/s41587-024-02282-4 (2024).
About this article
Cite this article
CRISPR screens of tumor-infiltrating NK cells identify genetic checkpoints for CAR-NK therapy.
Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02319-8
Download citation
Published: 25 June 2024
DOI: https://doi.org/10.1038/s41587-024-02319-8
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/s41587-024-02319-8